Hallucinogen Rating Scale
The Hallucinogen Rating Scale (HRS) is a psychometric scale for measuring the subjective effects of hallucinogens like psychedelic drugs and other psychoactive drugs.[1][2][3][4] It includes 100 items that are mostly on a 5-point Likert scale and 6 factors/subscales (somaesthesia, affect, perception, cognition, volition, and intensity).[1][3][4] The HRS is one of the most widely used scales for measuring hallucinogen effects, following the 5D-ASC and 11-ASC scales.[1][2][3][5] It has been revised several times and has been translated into and validated in several different languages.[3][4][6][7] The HRS was developed by Rick Strassman and colleagues and first described in 1992.[3][8][9][10] It was first developed and used to assess the hallucinogenic effects of the psychedelic drug dimethyltryptamine (DMT).[1][3][4] Subsequently, it has also been used with a variety of other psychoactive drugs, including psilocybin, ayahuasca, 2C-B, meta-chlorophenylpiperazine (mCPP), ketamine, dextromethorphan (DXM), salvinorin A/Salvia divinorum, Δ9-tetrahydrocannabinol (THC), d-amphetamine, d-methamphetamine, 4-fluoroamphetamine, methylphenidate, MDMA, and MDEA.[1][2][5][7]
See also
[edit]References
[edit]- 1 2 3 4 5 Herrmann Z, Earleywine M, De Leo J, Slabaugh S, Kenny T, Rush AJ (2023). "Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials". J Psychoactive Drugs. 55 (4): 501–517. doi:10.1080/02791072.2022.2125467. PMID 36127639.
- 1 2 3 Prugger J, Derdiyok E, Dinkelacker J, Costines C, Schmidt TT (November 2022). "The Altered States Database: Psychometric data from a systematic literature review". Sci Data. 9 (1): 720. doi:10.1038/s41597-022-01822-4. PMC 9684144. PMID 36418335.
- 1 2 3 4 5 6 Hovmand OR, Poulsen ED, Arnfred S (January 2024). "Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics". J Psychopharmacol. 38 (1): 19–32. doi:10.1177/02698811231200019. PMC 10851631. PMID 37969069.
- 1 2 3 4 de Deus Pontual AA, Senhorini HG, Corradi-Webster CM, Tófoli LF, Daldegan-Bueno D (2023). "Systematic Review of Psychometric Instruments Used in Research with Psychedelics". J Psychoactive Drugs. 55 (3): 359–368. doi:10.1080/02791072.2022.2079108. PMID 35616606.
- 1 2 Bouso JC, Pedrero-Pérez EJ, Gandy S, Alcázar-Córcoles MÁ (September 2016). "Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens". Hum Psychopharmacol. 31 (5): 356–372. doi:10.1002/hup.2545. PMID 27470427.
- ↑ Riba J, Rodríguez-Fornells A, Strassman RJ, Barbanoj MJ (May 2001). "Psychometric assessment of the Hallucinogen Rating Scale". Drug Alcohol Depend. 62 (3): 215–223. doi:10.1016/s0376-8716(00)00175-7. PMID 11295326.
- 1 2 Calder AE, Qualls C, Hasler G, Elmiger D, Strassman R (March 2025). "The Hallucinogen Rating Scale: Updated Factor Structure in a Large, Multistudy Sample". Biol Psychiatry Glob Open Sci. 5 (2) 100436. doi:10.1016/j.bpsgos.2024.100436. PMC 11804565. PMID 39926700.
- ↑ Strassman, R. (1992). Subjective effects of DMT and the development of the Hallucinogen Rating Scale. Newsletter of the Multidisciplinary Association for Psychedelic Studies, 3(2), 2–. https://scholar.google.com/scholar?cluster=14254000933395729662
- ↑ Strassman RJ (1994). "Human hallucinogenic drug research: regulatory, clinical, and scientific issues" (PDF). NIDA Res Monogr. 146: 92–123. PMID 8742796.
- ↑ Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (February 1994). "Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale". Arch Gen Psychiatry. 51 (2): 98–108. doi:10.1001/archpsyc.1994.03950020022002. PMID 8297217.
.png){kind=small} | This article about psychological testing is a stub. You can help Wikipedia by adding missing information. |